<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301256739
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BRONCAST 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Broncast 10 mg film-coated tablet is</p><p>Broncast 10 mg film-coated tablet called (‛Broncast&rsquo; in this leaflet), is a leukot- riene receptor antagonist that blocks substances called leukotrienes.</p><p>How Broncast works</p><p>Leukotrienes cause narrowing and swelling of airways in the lungs and cause allergy symptoms. By blocking leukotrienes, Broncast improves asthma symp- toms, helps control asthma and improves seasonal allergy symptoms (also known as hay fever or seasonal allergic rhinitis).</p><p>When Broncast should be used</p><p>Your doctor has prescribed Broncast to treat asthma, preventing your asthma symptoms during the day and night.</p><p>&bull; Broncast is used for the treatment of adults and adolescents 15 years of age and older who are not adequately controlled on their medication and need ad- ditional therapy.</p><p>&bull; Broncast also helps prevent the narrowing of airways triggered by exercise.</p><p>&bull; In those asthmatic patients in whom Broncast is indicated in asthma, Broncast can also provide symptomatic relief of seasonal allergic rhinitis.</p><p>Your doctor will determine how Broncast should be used depending on the symptoms and severity of your asthma.</p><p>What is asthma?</p><p>Asthma is a long-term disease. Asthma includes:</p><p>&bull; difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</p><p>&bull; sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</p><p>&bull; swelling (inflammation) in the lining of airways.</p><p>Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p><p>What are seasonal allergies?</p><p>Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an allergic response often caused by airborne pollens from trees, grasses and weeds. The symptoms of seasonal allergies typically may include stuffy, runny, itchy nose; sneezing; watery, swollen, red, itchy eyes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you have now or have had.</p><p>Do not take Broncast</p><p>&bull; if you are allergic to montelukast or any of the other ingredients of this medi- cine (listed in section 6).</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Broncast.</p><p>&bull; If your asthma or breathing gets worse, tell your doctor immediately.</p><p>&bull; Oral Broncast is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you. Always have your inhaled rescue medicine for asthma attacks with you.</p><p>&bull; It is important that you or your child take all asthma medications prescribed by your doctor. Broncast should not be substituted for other asthma medications your doctor has prescribed for you.</p><p>&bull; Any patient on anti-asthma medicines should be aware that if you develop a combination of symptoms such as a flu-like illness, pins and needles or numb- ness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p>&bull; You should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medi- cines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your asthma worse.</p><p>You should be aware that various neuropsychiatric events (for example behav- iour and mood-related changes) have been reported in adults, adolescents and children with Broncast (see section 4). If you develop such symptoms while taking Broncast, you should consult your doctor.</p><p>Children and adolescents</p><p>Do not give this medicine to children less than 15 years of age.</p><p>There are different form(s) of this medicine available for paediatric patients un- der 18 years of age based on age range.</p><p>Other medicines and Broncast</p><p>Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines including those obtained without a prescription.</p><p>Some medicines may affect how Broncast works, or Broncast may affect how other medicines work.</p><p>Tell your doctor if you are taking the following medicines before starting Bron- cast:</p><p>&bull; phenobarbital (used for treatment of epilepsy)</p><p>&bull; phenytoin (used for treatment of epilepsy)</p><p>&bull; rifampicin (used to treat tuberculosis and some other infections)</p><p>&bull; gemfibrozil (used for treatment of high lipid levels in plasma)</p><p>Broncast with food and drink</p><p>Broncast 10 mg film-coated tablet may be taken with or without food. Pregnancy and breastfeeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are plan- ning to have a baby, ask your doctor or pharmacist for advice before taking Broncast.</p><p><u>Pregnancy</u></p><p>Your doctor will assess whether you can take Broncast during this time. <u>Breast-feeding</u></p><p>It is not known if Broncast appears in breast milk. You should consult your doc- tor before taking Broncast if you are breast-feeding or intend to breast-feed.</p><p>Driving and using machines</p><p>Broncast is not expected to affect your ability to drive a car or operate machin- ery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with Broncast may affect some patients&rsquo; ability to drive or operate machinery.</p><p>Broncast 10 mg film-coated tablets contain lactose and sodium</p><p>If you have been told by your doctor that you have an intolerance to some sug- ars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&bull; You should take only one tablet of Broncast once a day as prescribed by your doctor.</p><p>&bull; It should be taken even when you have no symptoms or have an acute asthma attack.</p><p><u>For adults and adolescents 15 years of age and older</u></p><p>The recommended dose is one 10 mg tablet to be taken daily in the evening.</p><p>If you are taking Broncast, be sure that you do not take any other products that contain the same active ingredient, montelukast.</p><p>This medicine is for oral use.</p><p>You can take Broncast 10 mg with or without food. <strong>If you use more Broncast than you should </strong>Contact your doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p>If you forget to use Broncast</p><p>Try to take Broncast as prescribed. However, if you miss a dose, just resume the usual schedule of one tablet once daily.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you stop using Broncast</p><p>Broncast can treat your asthma only if you continue to take it.</p><p>It is important to continue taking Broncast for as long as your doctor prescribes. It will help control your asthma.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In clinical studies with montelukast film-coated tablet, the most commonly re- ported side effects (may affect up to 1 in 10 people) thought to be related to Broncast were:</p><p>&bull; abdominal pain</p><p>&bull; headache</p><p>These were usually mild and occurred at a greater frequency in patients treated with Broncast than placebo (a pill containing no medication).</p><p>Serious side effects</p><p><strong>Talk with your doctor immediately </strong>if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing</p><p>&bull; behaviour and mood related changes: agitation including aggressive behav- iour or hostility, depression</p><p>&bull; seizure</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&bull; increased bleeding tendency</p><p>&bull; tremor</p><p>&bull; palpitations</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&bull; combination of symptoms such as flu-like illness, pins and needles or numb- ness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg- Strauss syndrome) (see section 2)</p><p>&bull; low blood platelet count</p><p>&bull; behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and actions</p><p>&bull; swelling (inflammation) of the lungs</p><p>&bull; severe skin reactions (erythema multiforme) that may occur without warning</p><p>&bull; inflammation of the liver (hepatitis)</p><p>Other side effects while the medicine has been on the market</p><p>Very common: the following may affect more than 1 in 10 people</p><p>&bull; upper respiratory infection</p><p>Common: the following may affect up to 1 in 10 people</p><p>&bull; diarrhoea, nausea, vomiting</p><p>&bull; rash</p><p>&bull; fever</p><p>&bull; elevated liver enzymes</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; behaviour and mood related changes: dream abnormalities, including night- mares, trouble sleeping, sleepwalking, irritability, feeling anxious, restlessness</p><p>&bull; dizziness, drowsiness, pins and needles/numbness</p><p>&bull; nosebleed</p><p>&bull; dry mouth, indigestion</p><p>&bull; bruising, itching, hives</p><p>&bull; joint or muscle pain, muscle cramps</p><p>&bull; bedwetting in children</p><p>&bull; weakness/tiredness, feeling unwell, swelling</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&bull; behaviour and mood related changes: disturbance in attention, memory im- pairment, uncontrolled muscle movements</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&bull; tender red lumps under the skin, most commonly on your shins (erythema nodosum)</p><p>&bull; behaviour and mood related changes: obsessive-compulsive symptoms, stut- tering</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Store below 30&deg;C.</p><p>&bull; Store in the original package in order to protect from light and moisture.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines if you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Broncast contains</p><p>&bull; The active substance is montelukast. Each tablet contains montelukast sodi- um which corresponds to 10 mg of montelukast.</p><p>&bull; The other ingredients are: Lactose, Crosscarmellose sodium, Colloidal sili- cone dioxide, Mg-stearate, Hypromellose 606, Titanium dioxide, Yellow Iron Oxide and Red Iron Oxide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Broncast looks like and contents of the pack
Broncast 10 mg film-coated tablets are Paige, compact, biconvex, 8 x 8 mm square curved edges film coated tablets embossed with MF in one side.
Broncast 10 mg film-coated tablets are available in blister packages of 28 Film-coated tablets and 504 Film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Company (Avalon Pharma) P.O.Box 4180 Riyadh 11491</p><p>2nd Industrial City, Riyadh, Kingdom of Saudi Arabia Tel: +966 (11) 2653948 -2653427</p><p>Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was approved in [10/2024]

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو برونكاست ١٠ ملجم أقراص مُغلَفة؟</p><p dir="RTL">برونكاست ١٠ ملجم أقراص مُغلَفة يُسمى &laquo;)برونكاست&raquo; في هذه النشرة(، هو مضاد لمستقبلات الليكوترين الذي يمنع مواد تسمى اللوكوترايينات.</p><p>كيف يعمل برونكاست؟</p><p dir="RTL">الليوكوترين يُسبب تضييق الممرات الهوائية وتورُم في الرئتين، ويسبب أيضًا أعراض الحساسية. ويعمل برونكاست من خلال منع الليوكوترين على تحسين أعراض الربو، ويُساعد على التَحكُم في الربو، ويُحسّن أعراض الحساسية الموسمية )المعروف أيضًا باسم حمى القش أو حساسية الأنف الموسمية.(</p><p>متى يجب استخدام برونكاست؟</p><p dir="RTL">طبيبك قد وصف لك برونكاست لعلاج الربو، ومنع أعراض الربو أثناء الليل والنهار.</p><p dir="RTL">&bull; يُستخدم برونكاست لعلاج المرضى البالغين والمراهقين فوق ١5 سنة، وكبار السن الذين لا يستجيبون بشكلٍ كافٍ لأدوية الربو وبالتالي فهم بحاجة لعلاجٍ اضافيٍّ.</p><p dir="RTL">&bull; يُساعد برونكاست أيضًا على منع تضييق الممرات الهوائية الناجمة عن ممارسة الرياضة.</p><p dir="RTL">&bull; لدى هؤلاء المرضى المصابون بالربو )الذين وُصِف لهم برونكاست لعلاج الربو(، يمكن أن يخفف برونكاست من أعراض التهاب الأنف التحسسي الموسمي.</p><p dir="RTL">طبيبك سوف يُحدد لك كيفية استخدام برونكاست على حسب الأعراض ومدى شدة مرض الربو.</p><p>ما هو الربو؟</p><p dir="RTL">الربو هو مرض مزمن. الربو يشمل ما يلي:</p><p dir="RTL">&bull; صعوبة في التنفس بسبب ضيق الشعب الهوائية. وهذا التضييق في الممرات الهوائية يتفاقم ويتحسن تبعًا للظروف المختلفة.</p><p dir="RTL">&bull; الممرات الهوائية الحساسة تتأثر بالعديد من المؤثرات، مثل: )دخان السجائر، غبار الطلع، الهواء البارد، أو ممارسة الرياضة.(</p><p dir="RTL">&bull; تورم )التهاب( في بطانة الشعب الهوائية.</p><p dir="RTL">وتشمل أعراض الربو ما يلي: السعال، أزيز، ضيق في الصدر.</p><p>ما هي الحساسية الموسمية؟</p><p dir="RTL">الحساسية الموسمية )المعروفة أيضًا باسم حمى القش أو حساسية الأنف الموسمية( هي استجابة للحساسية التي غالبًا ما يسببها اللقاح الذي يحمله الجو من الأشجار والحشائش والأعشاب الضارة. أعراض الحساسية الموسمية وعادة ما يمكن أن تشمل: انسداد الأنف، سيلان، حكة الأنف، عطس، وتورُم، احمرار، حكة في العينين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبيبك عن أي مشاكل طبية أو حساسية تعاني منها الآن أو كنت تعاني منها من قبل.</p><p>لا تتناول برونكاست في الحالات التالية.</p><p dir="RTL">&bull; إذا كنت تعاني من الحساسية تجاه دواء برونكاست أو تجاه أيٍّ من المكونات الأخرى لهذا الدواء )المُدرجة في القسم .(6</p><p>التحذيرات والاحتياطات</p><p dir="RTL">تحدَث إلى طبيبك أو الصيدلي قبل تناول برونكاست.</p><p dir="RTL">&bull; إذا كنت تعاني من الربو أو يزداد تنفسك سوءًا؛ فأخبر طبيبك فورًا.</p><p dir="RTL">&bull; تناول برونكاست عن طريق الفم ليس المقصود منه علاج نوبات الربو الحادة. وفي حالة حدوث نوبات؛ اتبع تعليمات الطبيب التي أبلغك بها. واحرص دائمًا على أن يكون معك الدواء المُعالج الذي تستنشقه في حالات نوبة الربو.</p><p dir="RTL">&bull; من المهم أن تتناول أنت أو طفلك جميع أدوية الربو التي وصفها الطبيب. ولا يجب الاستعاضة ببرونكاست عن أدوية الربو الأخرى التي وصفها لك الطبيب.</p><p dir="RTL">&bull; ينبغي على أي مريض يتناول أدوية مضادة للربو أن يدرك أنه في حال ظهرت لديه مجموعة من الأعراض، مثل: اعتلال يشبه مرض الأنفلونزا، الشعور بوخز أو خدر في الذراعين والساقين، تدهور الأعراض الصدرية أو الطفح الجلدي، وفي هذه الحالة عليه أن يقوم باستشارة الطبيب الخاص به.</p><p dir="RTL">&bull; يجب ألا تأخذ حمض أسيتيل الساليسيليك )الأسبرين( أو الأدوية المضادة للالتهابات )المعروفة أيضًا مثل الأدوية المضادة للالتهابات غير الستيرويدية أو مضادات الالتهاب غير الستيرويدية( إذا أدت إلى زيادة الربو.</p><p dir="RTL">يجب أن تكون على علم بأن العديد من الأحداث العصبية والنفسية، على سبيل المثال: )التغيرات المتعلقة بالسلوك والمزاج ( قد تم الإبلاغ عن حدوثها لدى البالغين والمراهقين والأطفال الذين يتناولون برونكاست )انظر القسم .(4 إذا عانيت من مثل هذه الأعراض أثناء تناول برونكاست يجب عليك استشارة الطبيب. <strong>الأطفال</strong><strong> </strong><strong>والبالغون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال دون سن ١5 سنة.</p><p dir="RTL">توجد أشكال مختلفة من هذا الدواء متوفرة للمرضى من الأطفال دون سن ١8 سنة حسب الفئة العمرية.</p><p>برونكاست والأدوية الأخرى</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا أو تناولت مؤخرًا أو قد تتناول في المستقبل أيَ أدوية أخرى؛ بما في ذلك التي تحصل عليها دون وصفه طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل برونكاست أو قد يؤثر برونكاست على كيفية عمل الأدوية الأخرى أخبر طبيبك إذا كنت تأخذ الأدوية التالية قبل البدء في أخذ برونكاست.</p><p dir="RTL">&bull; (فينوباربيتال )الذي يستخدم لعلاج الصرع.</p><p dir="RTL">&bull; (فينيتوين )الذي يستخدم لعلاج الصرع.</p><p dir="RTL">&bull; (ريفامبيسِين )الذي يستخدم لعلاج السل وبعض الالتهابات الأخرى.</p><p dir="RTL">&bull; (جمفبروزيل )الذي يستخدم لعلاج ارتفاع مستويات الدهون في البلازما.</p><p>برونكاست مع الطعام والشراب</p><p dir="RTL">برونكاست ١٠ أقراص ملجم مُغلَفة يمكن أن يؤخذ مع الطعام أو بدونه.</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">إذا كنتِ حاملًا أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين لإنجاب طفل؛ فاسألي طبيبك للحصول على المشورة قبل أخذ برونكاست.</p><p>الحمل</p><p dir="RTL">سوف يُحدد طبيبك ما إذا كان بالإمكان تناول برونكاست خلال هذا الوقت أم لا.</p><p>الرضاعة الطبيعية</p><p dir="RTL">لا يُعرف ما إذا كان برونكاست يُفرَز في حليب المرضعات أم لا. ويجب استشارة الطبيب قبل تناول برونكاست، وذلك إذا كنتِ تمارسين الرضاعة الطبيعية أو تنوين إرضاع طفلك.</p><p>القيادة واستخدام الآلات</p><p dir="RTL">من غير المتوقع أن يؤثر برونكاست على القدرة على قيادة السيارة أو تشغيل الآلات. ومع ذلك فقد تختلف استجابات الفرد للدواء. وبعض الآثار الجانبية التي تم الإبلاغ عنها مع برونكاست، مثل: )الدوخة والنعاس( قد تؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات.</p><p>تحتوي أقراص برونكاست ١٠ ملجم المُغلَفة على اللاكتوز والصوديوم</p><p dir="RTL">إذا أخبرك طبيبك أن لديك عدم تحمُل لبعض السكريات )اللاكتوز أو سكر الحليب(؛ فتواصل مع طبيبك قبل أخذ هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&bull; يجب أن تأخذ قرصًا واحدًا فقط من برونكاست مرة واحدة يوميًا على النحو الذي يُحدده الطبيب.</p><p dir="RTL">&bull; ينبغي تناوله أيضًا حتى وإن لم يكن لديك أعراض، أو كانت لديك نوبة ربو حادة.</p><p dir="RTL"><u>بالنسبة للبالغين والمراهقين من عمر </u><u>١5 سنة وما فوق</u><u>: </u></p><p dir="RTL">الجرعة الموصى بها: قرص واحد ١٠ ملجم يؤخذ يوميًا في المساء.</p><p dir="RTL">إذا كنت تتناول برونكاست فتأكد من أنك لا تأخذ أيًا من المنتجات الأخرى التي تحتوي على نفس العنصر النشط )مونتيليوكاست.(</p><p dir="RTL">هذا الدواء للاستخدام عن طريق الفم. يمكنك أخذ برونكاست مع أو بدون الطعام.</p><p>إذا تناولت جرعة زائدة من أقراص برونكاست</p><p dir="RTL">اتصل بطبيبك على الفور للحصول على المشورة.</p><p dir="RTL">لم يتم الإبلاغ عن أي آثار جانبية في غالبية التقارير المتعلقة بتجاوز جرعة الدواء. وأكثر الآثار الجانبية التي تم الإبلاغ عنها مع تجاوز جرعة الدواء لدى الكبار والأطفال شملت: آلام في البطن، والنعاس، والعطش، والصداع، والتقيؤ، وفرط النشاط.</p><p>إذا نسيت أن تتناول برونكاست</p><p dir="RTL">حاول أن تناول برونكاست كما هو موصوف لك. وفي حال نسيانك تناول جرعة فليس عليك سوى استئناف الجدول الزمني المعتاد وهو عبارة عن قرص واحد مرة واحدة يومياً.</p><p>&nbsp;</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسيَة.</p><p>إذا توقفت عن تناول برونكاست</p><p dir="RTL">لا يمكن أن يعالج برونكاست الربو لديك إلا إذا داومت على تناوله.</p><p dir="RTL">ومن المهم أن تواصل تناول برونكاست طوال الفترة التي وصفها الطبيب لك. وسوف يساعدك في السيطرة على الربو.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى عن كيفية استخدام هذا الدواء؛ فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من أنها ليست شائعة بين الجميع.</p><p dir="RTL">في الدراسات السريرية التي تقوم على تناول مونتيليوكاست أقراص مُغلَفة، فإن الآثار الجانبية الأكثر شيوعًا والتي يتم الإبلاغ عنها )قد يؤثر على ما يصل إلى شخص واحد من كل ١٠ أشخاص( يُعتقد أنها ذات صلة ببرونكاست كانت كالتالي:</p><p dir="RTL">&bull; ألم البطن.</p><p dir="RTL">&bull; الصداع.</p><p dir="RTL">هذه الأعراض عادةً ما كانت خفيفة، وحدثت بتكرار أكبر لدى المرضى الذين كانوا يعالجون باستخدام برونكاست أو باستخدام العلاج الوهمي )الحبوب التي لا تحتوي على الدواء.(</p><p>الآثار الجانبية الخطيرة:</p><p dir="RTL"><strong>تحدَث مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورًا</strong> إذا لاحظت أيًا من الآثار الجانبية التالية، والتي قد تكون خطيرة وتحتاج إلى<strong> </strong>علاجٍ طبي عاجل.</p><p dir="RTL">غير شائعة: قد تؤثر على ما يصل إلى ١ من كلِّ ١٠٠ شخصٍ.</p><p dir="RTL">&bull; التفاعلات التحسسية بما في ذلك تورُم في الوجه والشفتين واللسان، و/أو الحلق؛ مما قد يسبب صعوبة في التنفُس أو البلع.</p><p dir="RTL">&bull; التغيُرات المتعلقة بالسلوك والمزاج: اضطراب بما في ذلك السلوك العدواني أو العداء، والاكتئاب.</p><p dir="RTL">&bull; نوبات تشنج.</p><p dir="RTL">نادرة: قد تؤثر على ما يصل إلى ١ من كل ١,٠٠٠ شخص.</p><p dir="RTL">&bull; زيادة الميل للنزيف.</p><p dir="RTL">&bull; الرعشة.</p><p dir="RTL">&bull; دقات قلب سريعة.</p><p dir="RTL">نادرة جدًا: قد تؤثر على ما يصل إلى ١ من كلِّ ١٠,٠٠٠ شخص.</p><p dir="RTL">&bull; مزيج من الأعراض مثل: اعتلال يشبه مرض الأنفلونزا، الشعور بوخز أو خدر في الذراعين والساقين، تدهور الأعراض الصدرية أو الطفح الجلدي )متلازمة شيرغ ستروس( )انظر القسم .(2</p><p dir="RTL">&bull; انخفاض عداد صفائح الدم.</p><p dir="RTL">&bull; التغيُرات المتعلقة بالسلوك والمزاج: الهلوسة والارتباك والأفكار والأعمال الانتحارية.</p><p dir="RTL">&bull; تورُم )التهاب( الرئتين.</p><p dir="RTL">&bull; تفاعلات جلدية حادة )حمامي عديدة الأشكال( قد تحدث دون سابق إنذار.</p><p dir="RTL">&bull; التهاب الكبد.</p><p>الآثار الجانبية الأخرى التي تم الابلاغ عنها بعد طرح الدواء في السوق:</p><p dir="RTL">شائعة جدًا: قد تؤثر على ما يصل إلى ١ من كلٍّ ١٠ أشخاص.</p><p dir="RTL">&bull; عدوى الجهاز التنفسي العلوي.</p><p>&nbsp;</p><p dir="RTL">شائعة: قد تؤثر على ما يصل إلى ١ من كلِّ ١٠ أشخاص.</p><p dir="RTL">&bull; الإسهال، والغثيان، والتقيؤ.</p><p dir="RTL">&bull; طفح جلدي.</p><p dir="RTL">&bull; الحمى.</p><p dir="RTL">&bull; ارتفاع إنزيمات الكبد.</p><p dir="RTL">غير شائعة: قد تؤثر على ما يصل إلى ١ من كلِّ ١٠٠ شخص.</p><p dir="RTL">&bull; التغيرات المتعلقة بالسلوك والمزاج واضطراب الأحلام، بما في ذلك: )الكوابيس، وصعوبة النوم، والمشي أثناء النوم، والتهيُج، والشعور بالقلق والأرق.(</p><p dir="RTL">&bull; الدوخة، والنعاس، والشعور بوخز أو خدر.</p><p dir="RTL">&bull; رعاف )نزف أنفي.(</p><p dir="RTL">&bull; جفاف الفم، وعسر الهضم.</p><p dir="RTL">&bull; الكدمات، والحكة، الشرى.</p><p dir="RTL">&bull; آلام المفاصل أو العضلات، وتشنجات العضلات.</p><p dir="RTL">&bull; التبول اللاإرادي عند الأطفال.</p><p dir="RTL">&bull; الضعف / التعب، والشعور بالإعياء، والتورُم.</p><p>&nbsp;</p><p dir="RTL">نادرة: قد تؤثر على ما يصل إلى ١ من كل ١.٠٠٠ شخص.</p><p dir="RTL">&bull; التغيرات المتعلقة بالسلوك والمزاج: اضطراب في الانتباه، وضعف الذاكرة، وحركات عضلية لا يمكن التحكُم فيها.</p><p dir="RTL">نادرة جدًا: قد تؤثر على ما يصل إلى ١ من كل ١٠,٠٠٠ شخص.</p><p dir="RTL">&bull; كتل حمراء طرية تحت الجلد، تكون أكثر شيوعًا على السيقان )حمامي عقدية.(</p><p dir="RTL">&bull; التغيرات المتعلقة بالسلوك والمزاج: أعراض الوسواس القهري، التأتأة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>&nbsp;يُحفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</li><li>يُحفظ في درجة حرارة أقل من 3٠ درجة مئوية.</li><li>يُحفظ في العبوة الأصلية لتحميه من الضوء والرطوبة.</li><li>لا تتناول هذا الدواء بعد تاريخ الانتهاء الموضح على الملصق والعلبة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</li><li>ينبغي عدم التخلُص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلُص من الأدوية التي لم تعد لازمة. ستساعد هذه التدابير في حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما يحتوي عليه برونكاست</p><p dir="RTL">&bull; المادة الفعَالة هي مونتيليوكاست. كل قرص يحتوي على الصوديوم مونتيليوكاست، وهو ما يعادل١٠ ملجم من مونتيليوكاست.</p><p dir="RTL">المكونات الأخرى هي: اللاكتوز، كروس كارميلوز الصوديوم، ثاني أكسيد السيليكون الغروي، وستيرات المغنيسيوم، هايبروميلوز 6٠6، ثاني أكسيد التيتانيوم، أكسيد الحديد الأصفر والأحمر أكسيد الحديد.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو برونكاست، وما محتويات العلبة؟</p><p dir="RTL">أقراص برونكاست ١٠ ملجم هي أقراص ذات لون بيج، مضغوطة، محدبة الوجهين، بحواف منحنية مربعة الشكل 8 &times; 8 مم، أقراص مغلفة بفيلم منقوشة بـ MF في جانب واحد.</p><p dir="RTL">تتوفر أقراص برونكاست ١٠ ملجم المغلفة في عبوات تحتوي على 28 قرصًا مغلفًا و5٠4 أقراص مغلفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة الشرق الأوسط للصناعات الدوائية )أفالون فارما( ص.ب. 4١8٠ الرياض ١١49١</p><p dir="RTL">المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف 3427 265 &ndash; 3948 265 (١١) 966 ٠٠</p><p>فاكس 4723 265 (١١) 966 ٠٠</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 10/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Broncast 10mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains montelukast sodium, which is equivalent to 10 mg montelukast.
Excipients with known effect: This medicine contains 158.2 mg lactose per tablet.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Paige, compact, biconvex, 8 x 8 mm square curved edges film-coated tablets embossed with MF in one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Broncast 10mg is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as- needed&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma.</p><p>Broncast 10mg is indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. Because the benefits of Montelukast may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions], reserve use for patients who have an inadequate response or intolerance to alternative therapies</p><p>Broncast 10mg is also indicated in the prophylaxis of asthma in which the predominant component is exercise- induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose for adults and adolescents 15 years of age and older with asthma, or with asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in the evening.</p><p><u>General recommendations</u></p><p>The therapeutic effect of Broncast on parameters of asthma control occurs within one day. Broncast may be taken with or without food. Patients should be advised to continue taking Broncast even if their asthma is under control, as well as during periods of worsening asthma. Broncast should not be used concomitantly with other products containing the same active ingredient, montelukast.</p><p>No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p><u>Therapy with </u>Broncast <u>in relation to other treatments for asthma</u> Broncast can be added to a patient&#39;s existing treatment regimen.</p><p><em>Inhaled corticosteroids: </em>Treatment with Broncast can be used as add-on therapy in patients when inhaled corticosteroids plus &ldquo;as needed&rdquo; short acting &beta;-agonists provide inadequate clinical control. Broncast should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p><em>Paediatric population</em></p><p>Do not give Broncast 10 mg film-coated tablets to children less than 15 years of age. The safety and efficacy of Broncast 10 mg film-coated tablets in children less than 15 years has not been established.</p><p>5 mg chewable tablets are available for paediatric patients 6 to 14 years of age. 4 mg chewable tablets are available for paediatric patients 2 to 5 years of age. <u>Method of administration</u></p><p>Oral use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p>Montelukast should not be substituted abruptly for inhaled or oral corticosteroids.</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.</p><p>Neuropsychiatric Events</p><p>Serious neuropsychiatric (NP) events have been reported with use of Montelukast. These postmarketing reports have been highly variable and included, but were not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thoughts and behavior (including suicide), tic, and tremor. NP events have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder. NP events have been reported mostly during Montelukast treatment, but some were reported</p><p>after Montelukast discontinuation. Animal studies showed that montelukast distributes into the brain in rats [see Clinical Pharmacology (5.1)]; however, the mechanisms underlying Montelukast -associated NP</p><p>events are currently not well understood. Based upon the available data, it is difficult to identify risk factors for or quantify the risk of NP events with Montelukast use.</p><p>Because of the risk of NP events, the benefits of Montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of Montelukast for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (4.1)]. In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing Montelukast.</p><p>Discuss the benefits and risks of Montelukast use with patients and caregivers when prescribing Montelukast. Advise patients and/or caregivers to be alert for changes in behavior or for new NP symptoms when taking Montelukast. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue Montelukast and contact a healthcare provider immediately. In many cases, symptoms resolved after stopping Montelukast therapy; however, in some cases symptoms persisted after discontinuation of Montelukast. Therefore, continue to monitor and provide supportive care until symptoms resolve. Re-evaluate the benefits and risks of restarting treatment with Montelukast if such events occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products:</p><p>theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).</p><p><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p>Available data from published prospective and retrospective cohort studies with montelukast use in pregnant women evaluating major birth defects have not established a drug-associated risk. Available studies have methodologic limitations, including small sample size, in some cases retrospective data collection, and inconsistent comparator groups.</p><p>Broncast may be used during pregnancy only if it is considered to be clearly essential.</p><p><u>Breast-feeding</u></p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p>Broncast may be used in breast-feeding only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Broncast has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies as follows:</p><p>&bull;&nbsp; 10 mg film-coated tablets in approximately 4,000 adult and adolescent asthmatic patients 15 years of age and older.</p><p>&bull;&nbsp; 10 mg film-coated tablets in approximately 400 adult and adolescent asthmatic patients with seasonal allergic rhinitis 15 years of age and older.</p><p>&bull;&nbsp; 5 mg chewable tablets in approximately 1,750 paediatric asthmatic patients 6 to 14 years of age.</p><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in asthmatic patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Adult and Adolescent Patients 15 years and older</strong></p><p><strong>(two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric</strong><strong> </strong><strong>Patients </strong><strong>6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201) (two 56-week studies; n=615)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p><u>Tabulated list of Adverse Reactions</u></p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection&dagger;</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor&sect;)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disturbance in attention, memory impairment, tic</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality), obsessive-compulsive symptoms, dysphemia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top; width:133px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:492px"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>pulmonary eosinophilia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:133px"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top; width:492px"><p>diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:133px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:492px"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:133px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:492px"><p>rash&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top; width:133px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:492px"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:133px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:492px"><p>enuresis in children</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:133px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:492px"><p>pyrexia&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:492px"><p>asthenia/fatigue, malaise, oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAmEAAAEnCAYAAADhHJSnAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAADPiSURBVHhe7d0/bhrP48bxZ3OMKIosljOkiHCKFF4OkAJcuYq01BE0Kd0s+tRGcuUqbOEDgAsXBqXIGVhkWVaOkfkVX2Z+s8OCsWNnnfj9klDM7L/Z2TU8mRlMZIwxAgAAwB/1KiwAAADA0yOEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADU4ElCWJ7niqJo62M+n4ebbbVcLtf24T+wu3a7rXa7HRY7vV5PzWYzLH40vV7PXbfhcChJGg6HrqzX64WbAADwz3mSEHZzc6Msy2SMkTFGcRwrTVP3PE1T3d7ehptt1Wg03LZxHLt9FUUhSQSxe5hMJppMJmGxtApIo9EoLH40NnQZY5RlmQaDgfI81+XlpYwxGo/HGo1GWi6X4aYAAPxTniSESVK/3w+LnC9fvoRFD9ZoNJRlmSTdu3ftseV5rjzPw+K/ysnJidI0DYsfzenpqT58+CCt7hFjjM7OzvTx40dJUqfTkTFGjUYj2HI323r4AAB4Tp4khG0LYFoFp06nExb/9brdbliEgO259C0Wi7DoQYbD4aPtCwCAp/YkIey+/Lld950PlOe5BoOB0jRVq9UqLfPnGflznObzuaIoKs0zC+dA2XXsw+/hssv8/dvh0G63u3FoNNyn32tj59HJaw+73J9DZcv8ulcN3fnHms/npfo3m821dm6324oq2sFqNptuf3ZIcZOqdf3zs21k268oCg0GA0VeO2+6duEyu89er6fBYKCiKErHtXXJ87x0zrYcAIDamD8gjmOTpmlYbIwxRpKZzWbGGGOKojCSNq5rjDFpmhpJpUeVLMtMlmXueZIkJkkSM5vN1rYNj2vXscbjsZFkxuNxafuwnnadTeI4dnWy+5nNZm7/fp385cargy9NU1MURanMiuPY/ezXK47jtbonSeKe27bwt4/j2B3HLt90nnetGz43QbuYLdfOLgvrZuseLsuyzB0rTVO3DwAAnoPqBPPINoWwLMvW3hht2NgULtI0dW+0WZZtXNeGjfBhvIDjb2f3ZVZv+n4IMMFxq7Y3GwJGFT90bQpZNsDY5aYirFS1qbWpzU2wLAycZsO5ho+qfe+yblUbhee17dopaBNfVQiz2wEA8NzUOhx5fX0dFunNmzeSpJ8/f4aL1vT7fSVJooODg3CRiqJQURSyn6K0j03evn3rfq6aV7S3t1c5n+k+7JDc1dXVg/Z1fHyswWAgrfZ1eHgYruIcHx9rNBqVhuyq3PUp1dvbWyVJstaOJycn4ar3WnebTdeuath1Gzs30bbB3/6hCQDAv6XWECZJ0+k0LJIkvX79OiyqNJlMVBTF2hynOI7148ePUtk2Nzc3iuPYPb+8vCwt12qfD7VcLtXtdjWbze4dSqxOp6M4jjUcDnV1dbU2B85nP2U4m82k1RyobTYFnDdv3my8RqH7rLvNpmtnPzF5V3D02QAXx7G63W7tn6AFAMCqNYTZP1XhT1D/9u2b0jS9158omM1mGo1Gpf18/vxZ3W63FC7CoHZ+fu5+HgwGOj4+lla9SNPptDQB/fT01C2/S57nG0ONDRBVIWMXtjdsb28vXFRiQ1er1XJBrIr9lKrfNqPRSEVRqNlsqtVqKY7jtT/9ELalVsfadd1ttl27NE03LvMNh0MNh0PX+7VYLH4rRAMA8OjC8cnHFE44V8U8Kjv3yT6q5hqZivUUzC1KvQn7dh9+mb++nbvkLw/ngIV1t9uG5f78pCRJSscPhXW0P4dzoMJjVM2huoudD2Uftt39Y9l6hm3rzwmz/OW647apWjc8J63aLiyz9dx07aqW2Wvg768oCpNl2cZrbNsBAIC6ROZ/b5ovynw+1/7+voqiuFeP23PR6/UePKQJAACeh1qHI3F/w+Fw64R8AADwd3iSnrBtn8YDnpsn+BUAAOBOTxLCAAAAsB3DkQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1ODJQ9hwOFQURYqiSM1mU5KU57nm83m46qPI89wdr91uS5J6vZ6iKFKe5+HqW9n6/q7lcunqFEVRuFhaHSuKIi2Xy3ARAAD4Bz1pCBsOhxoMBkqSRMYYXVxcKIoiff36Va1WK1z9UXQ6HaVpKkk6OjoqLbu5uSk936bX66koirD4QRqNhmazmSS5um3y8+fPsAgAAPyDImOMCQsfS7PZVFEUGo/H6nQ60qqn6urqSicnJ+Hqj8YetygKNRqNcPGdbHiUpMdqnl6vp9FopNls9mQBFAAA/D2etCfMurq6cj+/e/dOHz58KC1/TMvlUkVRKEmSBwWw+XzuAthjuri4kCQCGAAAkJ46hH3+/FmSNBqN3HysRqPhesUUzJeyc7eGw6EUzCezZXbOV6/Xq9xHHMeSpI8fP+40Fyt0dHSk8XgsSW5fCuaa9Xo9V1drPp+vnYc9ZxsM0zQtrRPu185h22V/dhlzyAAA+EuZJ5YkiZFkJJksy0rLZrOZkWSSJDHmf+N+RpIpisKtE8dxqSxNUyPJzGaz0j7SNK1cP1y+TRzHxhhjxuOxkeSeW1mWufPw62rXT9PUFEXhloXb2f2FdbTLx+OxMd7xN+3PL7PtAAAA/i5PHsJMEMRs0DBeGLH8oGK8sGFDWtU6YUCJ47i0PAxtm6Rp6tbZFMKSJDFxHLt17XJ/3ao62/O3whC2rR2q9gcAAP5+TzIcmed5aZhsMpm4ob2zszO3jh2i02r4Td4QpiSdn59Lq6FFrSa3S9LBwYG0Gq6UpCzLpNU+iqIo7WM0GimO461zsYbDoUajkfb39xVFkbrdbriKJGk6nUqSvnz5olarpcVi4epgj/njxw/J+2TmcrnUdDp152mHJuM4VqPRcHW2y+/aHwAA+Dc8SQi7urpyAcryg5G8yfqHh4eSpOPjY0nS+/fv3Tqnp6eSpE+fPmk+n2s0GkmSm9jvL1fFPuwcKhvaqsznc11fX2vVKyhjjJsT5vP35U/4v7y8lLw6fP36VVp9AEFeiLJ1tu1i2+Pbt2+l5XftDwAA/BueJIRdXFxoMBiU/iCrDUx+D5E1HA41nU4Vx7Fub2/dH3O1PUbyApYkvXnzxvUYWb1eb20fttft8PCwNOndms/nOjo6WvtzGVV/T8zu68uXL6XyxWLhfrZ/WyxJEp2fn2s+n7vtOp2O8jx3fzet3+9Lq546rUJWr9e7c392kr7/wQQAAPAXCscnf1dRFG4Cvj8XTMF8MDvvSqsJ6P7PxptQb+dH+ZPR7fwof4K8/3M4SV/BZH/jzSVTMF/M38Yeyx47nCNmgjr452HbINyf/+EE/5zsvu/any1jjhgAAH+3J/1jrQAAAKj2JMORAAAA2I4QBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUIDLGmLDwd0VRpCiKwmIAeBF+/foVFgHAmicJYa9eveJFCMCLxOsfgF0xHAkAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANXixIWw+n7/4PyjbbDaV53lYfKd2u63hcBgWQ9JwOFS73Q6LcYflcvnHfh/zPOcaAXgW/tkQZkNW1aPZbIar/xa73+VyuVY+n89LZVV6vZ56vZ57buu+y7ZPwb4h+o+XGLqazWbpumyy63p1GA6Hj34dnyJo/vfff8qyTPLu//D3NPyPU3iPhtcgvI/t/jqdjqbT6drvKwD8af9sCGu1WjLGyBij8XisOI7d88ViEa7+2+I4XnsTeChb91arFS76o4qikDFGRVFoMBg8qNfsb7ZYLHRychIWr9l1vT+t1+tpMBi4+94Yo8vLy9rC/Taj0Ujv378Pi+8MjbPZzJ3baDRy68/nc8VxrPF47JYfHx+739E0TXV+fh7sDQD+rH82hO0qz/ON/5NuNptu2V3/8z8+PtZ0Ot36BlfVI9FutzUajTQajVwd7P/g/f+p+3WJvN6A+XyuZrNZ6vEIz6PquPfRaDSUpqmurq5K5X6d/LqGvS+WHQbq9XquLmFZFEXK87zUk3mf8/GX+aGx3W6Xltn6RkGPo9/24bCrv7192H2H9bB2bYuo4lz89vWX7XJfzudzjUYjFUVRKp9MJi7c+8f267btnrLBbjqdlo4frdo78nqcwp6o8Pws2/7hfzqOj481GAxKZdtkWabLy0tJ0tHRkbIsU6fTccs7nY4Lyx8+fNDp6albBgB1ePEh7OrqyvX2jEYj94bQbrd1cHDg/hetO/5X/ubNG6VpqqOjo3CRtHrjtD1Ls9lMg8FAy+VSk8lEaZoqTVMZYyp7VJrNZqkuaZqWhmqKotD19XXleWw67u8aDAa6uLhw9bFv0nmeu7oYY5QkSSlETadT7e3tyRijfr+/VjYej9XtdnV0dHTv82k2m8qyzB3769ev0upaSnLlWZYpjmNJUpIk+vbt26p20vn5uZIkUaPRcGVa7cNeo9lsJq3afZv7tEV4LuH9ZwNDWK4N9+X3798Vx/HaeVjD4dBdP9smfqDbdE+dnJwoyzIlSSJjjCaTidvm69evMl5Pc9gTNRgMKv+T8v37dyVJEhar0+k8qId5uVyqKIrKnjXrzZs3d14/AHhy5glEURQW1Wo8Hps4jktls9nMhKefJIkZj8emKAojyRRF4ZZV7cOSZGazmft5PB6vlYf8ZWmamjRN3TL/+FX1vGu5PY8q/nHjOK5cLzx/ewy7XZIkJssyt/5sNtvYNlmWmSRJjNnQhmFZeGyz4/lUtYPZsD/jbTcej0vb+W3in2fYVpvawz/f0F1tEcexmc1mG+tcVV61H3NHPUzF+dznnqrat98eZkO9wvvcL/f35x/f/lxVL/+Ytv6bfn9Du6zzUM/t9Q/A8/Xie8JCNzc37uc4jt1QSrfbLa23ie3JCfnDa/7Qzy5sr41lezd+/vxZKvfZ8/jd40ZRpP39fc1ms7XhIp/fq+AP/d1nOGmbXc4nbCdf2CMUx7Fub2/dcNV8Ptd8PldRFKUhLKvZbLrhWNub8/r162Ctdfdti9vbW/dzWGfrIfdllW636/azre0s/3djF0VRlK7VaDQKV3E2nWur1Sr1tIb29/dd/cfjceW122bb7xAAPDVC2BZ22Ms+dpnQb4dQ/CGi5XLpgozd132EwyZ2yOquEPAYx7XbbQtgPvtmabezn3h7DHedT9hOvnAItigKvXnzRlpN0v727Zu+f/+uNE1L6/nsvL39/X2Nx+ONwcH63bYI62ztcl++f//+zk8A+kOF9nHXOd2H/2EY+6gabteWc5WkL1++aDqd6vv37+Gi0r1gA1ij0VAcxztNvL/rdwgAnhIhrEKj0VCSJPrvv//CRTs5Ozur7PWwL/jhpwz39vY2vgm1Wq21eTH//fdf5bylTTYd96n49XqKyc9V52NDYjiB3V5Lv/2Gw6HiOHbbHB4eajQa6fT0VIeHh24933Q6LYWfXXtcHtIWNkT4959/Lrvcl61WS0mS6ODgoFTe6/U0n8/1+fNnN2fuvt6+fVsZ/HydTkdFUex0z+3t7YVFJY1GQ1mWVf5ObWIn9ftz0ObzubsPbA/Yrr9DAPAUCGEbTCYTXVxclIZTNg2JhOwQilaBwb6J2GGks7Oz0vDPp0+f3KfNqiZZLxYL1wsTrT6550+I3uSu4z6Fk5OTUl3DEPA77jqfYvWnNOyxz87OpNW1XCwWrvz09LQUImzQtT9XsX/mxL8fqiaZ+36nLcJrfnx8LN3zvpxMJjo4OCitu7e3p1arpX6/v7bM/7DHNjZgbTu2VtfDH/KMgk+sWrbXbpt+v684jne+fzudjmazmRuujKJIR0dHrifu9vZ2530BwFOJjLnnGNUOXr16pV+/foXFwF9puVwqjmMVReF6TvI819evX+/sEcJuoii6c97hY7LhcdPw6O/g9Q/ArugJA+5QNXR1c3Ozc88R7pamaeWcr6cyGo02Dj0DwJ9CTxiwg+FwWJqTFMcxvWCPaD6fa39/X0/wcrQmz3OdnZ3tNKT/ELz+AdgVIQwAHhGvfwB2xXAkAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBD2DxsOh2q325Kk5XKpKIq0XC7D1QAAQA0IYTvo9XqKokhRFKnZbLryPM9duX30er21bexjOBx6e/1/w+FQURQpz/Nw0V+r3W5vPN/HYtvftrllA6d92CBqNZvN0nKfvRb24V+T+XxeWhYeFwCA+yCE3WE4HOri4kLGGBljdHx8XHpjjuPYLTPG6OTkxC1L07S0bDAYrAUCSTo9PVWapjo7OwsXYYNms6mrqyulaRouUhzHyrLMtftisXCBsN1uq9lsumVpmrprkue5BoOBiqKQMUaz2UzdblfL5VLL5VL7+/saj8du29Fo9E8FZwDAn/ViQ9iuvRrX19el3q9Op6NOp1NaZ1fGGE2n07XeFUn68uWLptPp1uFCvwfH72Vqt9sbe312EfboWWGPUnjMcDtb92azqel0qsFgUNoubHO/HZrNZml/8nqlqiwWi1LgtWx79vt9V3Z8fKzT01NJ0nQ61devX90yv91tqGs0GpKkVqulJEl0fn6uHz9+KI7j0rXPsozgDAB4sBcZwubzufb39zWbzUq9GlXDZ4eHh5pOpw8KN1WSJNHV1ZV7/u3bNx0cHKjRaLg3/CrtdlsHBweuvjZU9Ho9HR0dufIw5N1lPp+r2+263p/xeOzaIY7jUs/PYDBwIUdSabs0TV2QXSwWSpLE9Ub1+33Xk2TbvCgK18vk788e66Fev34trYKl9ebNGxVFIa3O6du3b26ZDVw/f/7U3t6eRqORW2aXX19fu3345//27VstFovS+gAA7OpFhrBv374pTVO1Wi1XlmWZLi8vS+tp1Rtiw01U0dNUFMXG3qIq9k3fGo1GOjw8lCQdHR25cOVbLpeaTqf68uWLK7Nv/icnJ6XemSRJdHNz457fxbaFrVen01G/31ee52s9P2malgJMlmVuu8PDw62B5Pz8XEmSuDavCp3j8djb4n+9WfcNZI1GQ+PxWN1u112T/f19t/zi4kKj0ah0zax+v68kSUrLbChrtVrKskz7+/tuWbfbddsCAHBfLzKESdLe3l7p+V29GraHZrFYlIJYOCfMHwar4vf82KBjg8m7d+9UFMXGnqwwwFl+aJhOp+HiO4VtYYUBM+wlCtnepk1skP2duu6i0+mUrsl4PFYcx9KqDf1lts62B20ymZSWJ0ni2seGQvvIsqw0VA0AwH282BB2fX1den5zc7PTG+rx8fHWsHaX6XSqDx8+SJLOzs5KQccGhU3zjKrmizWbzdIk9CRJwlXuFLaFFQZME3zw4L6SJFnb312h9TGcnZ3p4OAgLJZWPXRxHFcGXNsD+f79+3CRtPpAxcePH8NiAAB28iJD2OHhoUajUWl+z2Aw0NHRUWk9rUKOH37Ozs52CmtVms2mkiRRp9Nxb/D+vDSz6rUJJ+g3Gg3Fcaz//vuvtC/r7du3khca7uPDhw8ajUbueHmeazgcqtPpbO2Vu4udS2V9+vRJ0+m01OZ32TYxf1fD4XBtKNeaz+caDAY6Pj4OF0mSDg4OSkOovl6vp6Io/kiIBAD8o8wTiKIoLHp2xuOxkeQe4/E4XMUYY8xsNiutlySJWzYej00cx6X1rTRNS9tJMlmWueVZlpX25QvX9cvD+ob1S9PUbesfoygKI8kURVHap13Pbu+fj92m6rhJkpTqaOsRPt9WV0lmNpsZY4yJ43jtGth6VYnjeG1faZoaE7STgnNOkqS0zD9meE/416eqLYAqf8PrH4DnITL/e9N6VK9evdKvX7/CYgD45/H6B2BXL3I4EgAAoG6EMAAAgBoQwgAAAGpACAMAAKgBIQwAAKAGhDAAAIAaEMIAAABqQAj7CyyXS0VRVPm1Rc9Br9dTr9cLi5+dXq/nviKqqi3b7fadX8AOAMBjIYTdwQag8FH1Jv6YHuMre/41tk38x65fIbVcLjUajVQUhYwxld8VCQDAn0QI25F987aPp34T7/f7eoIvM/gr2SB8eXm59gXgnz9/3ikU//z5U1p9pyUAAM/Biw1h8/m81KPyWMNpzWZTeZ6v9dS02+3KXrSwd8fK83xjL0+73Va73Q6LpdUy//j+8ebz+Vr9wv349dzUJn7bhXXM81ztdtsN/Q2Hw7XhynB4NaxveOyDgwONx2NNJhNXZvX7fWVZVvpyc/8cbHvs7+9LUumct7WDVteyqj4hf5jTPuwXn4fnZoc7h8Ph2jHDdrLCfWxqt7uCKADgmQm/TPIxPPcvsLVfJG2/PNps+dLsbV98XcV+sXT43H5RdJqm7ouhx+Ox+9Jps/pyafvc/3LwsA5Jkmz88m/7BdV2Xf949rz9bf3z9tc1q31Vnbd/Pnaffr3DtkzTtHSe/vnYn+21COswHo/XvoTcHs+282w2c2216UvVwy8YD48b1jtJErcsXNdnt7PiOHb7sMtsG9r9jMdjVx+/fTcdo6p8NpuV2ilsN9Tnub/+AXg+XmRP2Ldv35SmqVqtlivLskyXl5el9XxxHO/UKyJJ4/HY/XxwcKA0TdXpdCRJh4eHWiwWkqROp6OTkxO37sePH3fqzZhMJpW9QlaWZW7YzT+e5W/rn/doNNLXr19L64XDd3meK45jdz6tVktpmpbWieNY/X6/VLaJHSa01+LDhw+l+p6dneno6Eha7Xc8HssYo729PSVJ4tbzFUVxZzuen58rSRJ33E6nU9rfZDJxyxqNhuI41u3trVtu3dzclLY7ODjQ9fW1tKq7fy0ajYbSNNXV1ZVarZbiONb5+bnktat/T/q+f/9eet5qtUrXMWw3AMDz9yJDmCTt7e2Vnr99+3brm5g/J8wGJ3+4Khxa2qYoCvezP3Q2GAxK6z0W/3iht2/flp6/fv269LxKOAT5O+zx5vO5JOnq6qq0/8VioXfv3mk+n5fCn1ahVauAcnBwIK3C1Hg8dqHZ7rdKGDB94QcyNrXh27dvNZ1O3fOLi4vSvRW2797enguInz9/dgH47OxMnz9/Lq1rGWM0GAzW/gPgD4N2u93SNgCA5+/FhjDbW2Hd3NzcO1wsFgsXzLb1TG1i31DtPrIsC1d5cjc3N6Xntmdqm21htUoYeKvs7+8riiKNRqNSW9rwc3t7667PcrnUYDBwAWcwGOjw8NBt0+l0ZIzReDx2c8GqbOst83vdjDGK4zhcpcSGoWazWeoFDNv3+vrahb9Pnz5pOp1quVxqOp3q06dPpXV9th6j0Uh5nms4HOri4sKV+72vAIC/w4sMYYeHhxqNRqVeksFg4Ia9/iS/N+b09LS0bJNtE/N34fem+OedJImOj4/dsna7reVyqV6v5wLQu3fvVBRFaeL5aDRy21R5+/ZtaR3/+D9+/FCSJC5MmIpPhP78+VOdTkfT6VRRFLmJ+t1uV1EUKcuyymG8N2/ehEXO+/fvNZ1O3T0wHA5LPVrytp/P52u9l7b9r66ulGVZZRg/OjrSYDBwYW+5+jMZNjA2Gg0lSaKDgwMlSeLuBfvBh6pePD8M+v9pODs7cz8DAP4OLzKEtVot10tiezDG43FpqCvkzwnb9AZ5XycnJxqNRm6fdkjtqe3t7blj+vPVJpOJFouFW/bx48e1IbtGo1EKQHbe0zZ2vpXdrx927bH9tvXDRZIkbj6UDTqLxcL1dhljSj1P/hDd/v6+ZrOZW+ZrtVrKsszdA9fX16W5bf79cXR0tHH+2cnJiRsqtA8bMjudjrIsc/dOHMeazWalwHh0dKSiKDb+ByD8FO/BwYE6nY76/X7pWoXXCQDw/EWmquvhN7169Uq/fv0Ki1Gz+Xyu/f39yt6mugyHQ11eXpZ6kNrttj5+/Kh+v6/lcqk4jpWmaelDDM+FX1criqK1sIWXg9c/ALt6kT1heD78OVLWYrFw870ajYaMMbq4uCj1CEUVf6OsDn5d5c0z2+UDDgCAl42esBfkOfaEaTW3yZ9zlWXZzn/iom62p85HL9jLxusfgF0RwgDgEfH6B2BXDEcCAADUgBAGAABQA0IYAABADQhhAAAANSCE4dmxf6A01Ov17vzydAAA/haEsBpEj/QX9x/DcDj8ra9Aegrfvn0r/fV6y//Kn13ZL+Le9j2R9+V/6XqVZrPpvtYJAIBNCGF3iKJo7Q3V/y5FX9W6jyU85p8Kcu12W8PhsFT21CHj4uJiLWzN53PFcVz739+az+eaTqcbv+cSAIBdEcLukKaprq6uSmUXFxcqiqIUguzP275/8necnJxosViExf8c245h2Pr27Zs+f/5cKqvD7e3t2h9nBQDgIV5sCAu/GHnTXKMPHz7o4uLCPbfDWv4XS0vS9+/fS1/ynOd5af9hr9Xt7W1pua/ZbK7Vyw4b2uE1Se4Lpu2+tx2z3W5vHXb0v/ja9nI1m01Np1P3BdXD4VBRFKkoCvcF3nmeK89z12MW1luruvv1suw+fZvC1mg00qdPn9xzv75hr6Q/XHh+fl5apuDLwjdddwX7sefX7XZVFEVp203nbVVdzyr+8exj07W17VY1T66q91IV+7D38qZyAMATM08giqKw6FmZzWZGkpnNZq5MksmyrLSeMcYURVFadzwemzRNTZZlJkkSt16SJGY8Hhvj7b8oitJzS5KJ47i0rd1XuF8rLA/rf9cx/WP4siwzklzdx+Px2nZhu8Rx7NY33jZpmhrjtdl4PHY/23r5qto8PC+z2r/fXlmWlbaL49g9z7JsrW394/vr2uf+uVjhMTeVh+0etmeSJO58wnvJF9a76prYY/jtG16vu9o7PPZsNivdF2maVt4n2N1zf/0D8Hy8yJ4wO/HbH/LKskyXl5el9bT6Amm/1+vs7EwfPnzQp0+fNJ1OtVwutVwuNZ1O9e7dO8nbv/1i6larpTiOS/Oozs7O3M9fv37VdDp1z/2fd3XXMSeTiSaTSbDV/yRJ4oZR7b/37Q2J41gnJyfSqs3CYdwfP354a/+PMab0HZF5nlfO+zo7Oyv1jvX7/dJ2BwcHur6+liSdnp7q+PjYLbN10qr3syiK0rafP38uXQtfURR3tkPY7v1+vzRcOZlM3Pk0Gg3Fcazb21u33Lq+vtbBwYF7niSJbm5upNX5Z1nmjuG3r71e9jqfn58rSZK1L0W3/N5bre4T/7748OHDixj2BoDn4EWGMEna29srPX/79u3GN5+PHz+6gGbDln1D/fHjh378+LH2xjcajUpDPP4XVIdev37tfu73+8qy7EFDQ/c55l1+/vwZFt2Lbd9Go1EavqwaJrPCsKVVGJxOp6WhSAVDfKPRqLTszZs3pechv40Gg0G4WFqF0fF4rDiOFVUMJ/vCe8lnh4/vuiZ7e3ulYe/pdKq3b9+65/7PWq1v7w0/8J6enuro6Ki0rmWMcUPL/hCmP7Tb7XZL2wAAns6LDWG258S6ublZm1tk2V4v+wk9G7YODg50dXWlq6srffz4sbRNmqbuE3T2sWnSfhh4+v2+jDHKsqzUO3KX+xzzqfnt22g0ZIxRURQaDAaVgWZT2Krq2Wm32zo4OHDnGP45i6qeJl/YRpt6CDudjowxGo/H2t/fDxc74b3ki+NY4/HYHWvbpH471yyKIqVpWrp2tlfMur6+dm1yeHio0Wik5XKpoii2XnNbj9FopDzPNRwOdXFx4crH43G4CQDgibzIEGbftPwwMBgMNvYg2F6vo6OjUiiy+7m4uND79+/Xyrf1YvnHOj4+XgsSquj98IXDWncd866J+Zs0Go21kNFsNtdCQVEUrpdruVxW/k2vcIjM7xmrClva0rPj9z75PWEHBwf6+vVr6bllh2g39cZtaqNtPWsfPnwotXuv11vr7bLb2+FQyz/e5eVlKaz5w6hHR0caDAbuGGH72vM6ODgo3Ud2wn3VPeGHQf8/H5uGZgEATyCcJPYY/oaJqXZCs31UTc722QnX4cRmBZPsrXD//mRpezxbXjWRPNwmnJhv6+Ovs+2Y2ybmh+XyztNOPLd1NsFxZrOZm6yepqkrt5Pfwzr5k+L951UT5MMPF1h28rl9pGnqPhRgVvvy66dgorq/rV8Hv438c7H7MRUT88N1bXtWtVUcx6Vl/vHCc/LrZYLr7dcnXO6X22MXRVG6jvI+RGGC9krTdO38cD9/w+sfgOchMv97U3pUr1690q9fv8Ji/KPyPNfXr183zqm7y3K5VBzHCm/F4XCo6+vrUq/Qv6rZbOr4+Lj0wYg4jlUUxVrvIJ43Xv8A7OpFDkfieTk/P68cjj09PV0b0vxXFUVRGva08wQJYADw76InDL/td3vC8L/5YuHkf3rB/k68/gHYFSEMAB4Rr38AdsVwJAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUIPIGGPCwt/16hXZDsDL9evXr7AIANY8SQgDAADAdnRZAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADV48hCW57miKCo9ms1muFqlXq/ntsnzPFz8ZIbD4Vqd5/O5tKpTaLlc3mv9cP+2PfI8d9tV8bcZDodaLpcaDofhagAA4C/wpCGs3W6r2+0qSRIZY2SMUVEUKopiY7DyQ8XJyYniOC4tf2pRFGkwGChNU1dnY4yOjo4URVG4unq9nqujv/7x8XHl+lX7v7i4UBRF6na74epOFEWlbSRVts1DQtlDtgEAAL/nyUJYr9fTdDqVJE0mE1feaDQ0Ho8lSd1uV8vl0i1bLpcaDAbu+Z9me6TSNNXJyUlp2WKxUJqmpbLhcKjRaCStAphvMpkoy7JS2ab9NxoNGWMqQ5VWPWSSdHh46Mr6/f5afR7Sfg/ZBgAA/L4nCWHL5dKFkzAoSNK7d+/cz//995/7eVMI+RPyPFdRFFIQdnxfvnwpPbfhpeoctQpK1i77Pz4+DotK9vf3S6E1rM9D2u8h2wAAgN/3JCHs58+f7ue9vb3SMq16fqyLiwtpNdxmRVFUOZfKzodqt9ul8nBOluXPvRoOh+55uL0knZ2duZ9fv35dWmY1Gg3Xg+UPpX748MFbq8yu7++/1Wp5a/y/TqdTuazT6bif4zh259hoNFzQ29R+7Xa71DZ+u27axj63Dxv8wnb229Eep+q6AQCAdU8Swm5vb8OirZbLpWazmXtujFkbDux2u27Ibjqdugns8/lccRy7eWdJkrhhv36/ryRJJK/Xyj7fxg+Jm9zc3IRFWy0Wi7DoXsLhTj/wbGq/PM81nU7dXDJJGo1Gms/nG7exQSuOYxljlKap6y3r9XqunW2vHgAAeJgnCWFv3rwJizZqNps7hR47j8yyQe/bt2+SpI8fP0qrAFUUxdqnDNM0Vb/f12QyKc1Ru0v4ScboHp/ufGzGmFI7jEYj9Xq9je3X6XQqA622BM3z83NJ0sHBgeT1ZOZ5rkajoel0qna7rUajUWrHyWSy8VgAAGDdk4Qwf0jt+vq6tEyrnhvLhqeHsvsaDAaKosjNRQt746qGRX1+PfwA1+/3S71QaZpqsVjo/fv3ruzq6sr9vIkNNQr2vwv75yjkBSs7D82e7zbz+bw09Bi2jc9er9FopGj1SU6tev5OTk6Upqmm06miDZ9uBQAAu3mSECbJfTKwKiTY3hYFk9cfwvbohH9Swp9HtQu/HrZ3bZtWq+WGNqvO0bJBxZ9Ev2n/20KN/wEGreaa7TK0GkWRjo6O1oYzN7Fh1f+zIsYY1z4nJycyq2Hhbrd770AJAAD+58lCmD8fy5/APZ/PXe+KPyfJt7zHHyG1k+JHo5HrLRoOhw8KB3ae02g02un4k8nEzZcKhyht75MNg41Gw51v1f57vd7WHjU79Ggtl0s33ytk28+uf3BwUOp9rGK3sT18/ry7PM+V57l6vZ4Liv4HDcTEfAAA7s88sdlsZiSVHkmShKsZY4xJksRIMnEcG2OMSdN0bTv/eVEUxhhjxuNxqTzLMmOMMVmWlcpns1npeJuE29nHJuHxteUcjXee/mM8HoerOVmWmdlstnYce55W2H7++nEcl45r2y7cxlRcszRNjVldD/+a+Me3+7HrAgCA7SKz6zgVAAAAHs2TDUcCAABgM0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFADQhgAAEANCGEAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADUghAEAANSAEAYAAFCDyBhjwkKURVGkKIrCYgAA8If9+vUrLPprEcJ28OrVq3/qogMA8Df6196PGY4EAACoASEMAACgBoSwJ7ZcLt2csvCR53lp3Xa7rXa7XSrD4xoOh2o2m2HxH2HvhfC642XK8/xJ5ppGUaThcBgWA3iGCGFPrNFoyBijNE0Vx7GMMe55t9t1L5btdlvT6TTcHI9oOBxqMBiExX/EcrlUHMdhMV6oPM/V7XbD4kdhjFG/3w+LATxDhLCanJycSJJOT08lSZPJREmSBGv9ux6rx28+n2/9X3+e567nqd/vK8uycJU/otFoqCiKsLg2y+VSvV4vLP4r9Xo9LZfLsPjBHuveDPlt3ul0NB6Pw1WexGO3D4DHQwirUZIkz+qN+U8ZDodaLBZh8YMcHR2FRSVP1dvwt/tXAth8PtdoNAqLH+wp2+Up973JY7cPgMdFCKvRYrG4c4iq3W67OWT+i7idT1K1bD6fu/L5fF6agxRut41/7LB3YDgclvbj/0/bzrvy58PZ+vV6PQ0GAxVFocibu9JsNjfuL5xXZ88niiIVRaHBYLBxG62CmP05XO7Xzer1em5ZeN6+ZrNZaof5fC7dY3tVnJvdh19mz9fu1+7TP46/nlbXrtfrla63Xd5sNjWdTjUajUrHDPn7Dnsb/XsjnGNXdez5fF66L6vuZb8twnbz29keL89z7e/vS5LiOC5t499Pft17vZ7a7XapLv6UgNFopOl0qmjD3L3w98eeh20PWwe/vtqhzXc57yi4x20723PN87w07zBsn/B3LLxfw98DAH+AwZ2iKAqL7i1NUxPHsXueZZmRZLIsc2VJkpgkSUrPZ7OZe+6vL8mMx2NjjDHj8dhIMkVRGGNM6TjhemmaumVhnXxJkrh1i6Io7SfLslI90zR1x7fnJcntO6xflmVrbeE/j+N47di2Hez+/XX9Ngz59Tbe9mHdrDRNS+v7dfHFcezO07dt+7Adi6IonXdVO4XHtu0wm81K6/rXMkkSVze7fXit/etbxa9nWK8kSUptHsfx1mPbMnvP+PuzP/vXxJ6bPUaWZRt/T8J2MKv62Od+m9v71K9LeD+laVq6t0Pb2iXcNry3wjb3z91UnMu23zO/ncNz9esY7tNU/M4URbH1XgCek8d4P35OCGE7eIyL7r8B2Ef4wue/ufgvqP4jfIPwQ499od0UHPwXbv/hv0Ab74V7E3mhyPKPGYaq8I0gXO6zdfLDQ9W5WOEbSkgVIWxb3cK2kRcOQlXHDrf1t/cDgQmunf/YFNKKolhrd+Nd120hKzzvcLkvfPP3Vd0b4XmF+w6PHbZ5GFZMEBpjL/D6j6p92efhw7+ftgWlcPkmVb934bbhvsN2CZfbdrTX2P/Z8n/Pwv2ZimsRto+pOG6WZWuvAcBz9Rjvx88Jw5G/yR+WqRpO8PmfjjTGuMn5VX7+/Lm2vjFGk8lE8oYpJGk2m5W2PT4+dsMedh2thj9ns9naPhuNRmn729vb0nPfpgm+dvjxoWxdjTGlDyj8zj7vyx4rbJ9d56/dd/vr62tlWba2fqfTkVaT+ZvNphsWOz8/V6vVctvbe+/r16+P+oGD6+vrsMipujfs/XNzcxMuerC9vT33c1EUKopirZ2q3N7eKkmStXW3/a7dx7bfu8e06b7/3d8zrT4UEMexG4a9vr5eew0A8GcQwn7TZDIpvdjbkPS7Xr9+raIoKl9w5/O5m1dV9VH0TqcjY4x7k7BzaJrNpr5//x6sve7NmzfSljcCSZX7eegLebvdVpqmlW+sjUZjaz0ek61/OF9nV/fdfm9vT5eXl2FxydHRkb5+/RoWuw83GGNKwewx7O3tbQyOVtU5vn37Nix6sOvra3ffxnGsHz9+hKtUevPmzZP9qZe7fu+ewmP+nvmOj481GAw0n8/14cOHcDGAP4QQ9kw1Gg0lSaKDg4NSuT959ufPn1LFC7V982q1WqX/rR8dHbkXXms4HK6FnFarpTiOK4/daDSUpmlpP8vlUtPpVF++fCmtvwv7v3G/Dv6b6OHhoabTaWlydZ7nayHATvzexE5avkuapm4ys3WfCcv32f7Tp09r5zYPPkjR6XRUFIXa7bY+ffrkyrXqIbLuCnObLJfLtQnonz59UlEUpXrbetleFP8c8zxXHMeuB++hbD2Wy6VGo5ELn58/f1a32y1dv6o2HQ6H7t4Ne6Sr1r9L+GEEa9PvnVa9zZatv98brQ1tHnrs3zMF5+Nfx9+9bgB+Qzg+iXW/MwZdNbfLn6Nk+fO1/Hkl4XwYO3fDXz/15pvNZrO1uUb+fI9wWTinyRce2+cf0z9GWO5PPtaqfv68HTvPyV/H7sO2Q9XysB6b5vHYdkpXc8v8/VTVzd8mLPdtqo/ZsH14H4Rzduyj6jzCuUZWWAf7s3/d7Lwhf11T8QGFUFjf8Pj+Mfx93HXsqja3Zf664e9I1X6sbWX2YYLrYufz+esUwQcFqmz7vQvbzO7f8ts8PHbYLvZcwvO2v2dhO5uKa2b3ET63xuPx1t9/4Dn6nffj5ygyVWNAKPnXvrUdeE7y1V+P56XozxoOh/r06dOjDG8Cf8q/9n7McCQAvECXl5cEMKBmhDAAtRkOh+5bDaLgj5Hi8fmf5n6sDxEBeDiGI3fwr3V/AgDwN/rX3o8JYTt49YoOQwAAngNCGAAAAH4LXTwAAAA1IIQBAADUgBAGAABQA0IYAABADQhhAAAANSCEAQAA1IAQBgAAUANCGAAAQA0IYQAAADX4P43Hb4EcOT7lAAAAAElFTkSuQmCC" alt="" width="609" height="295" vspace="0" hspace="0" border="0" style="width:609px;height:295px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42- month-old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p><u>Symptoms of overdose</u></p><p>The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p><u>Management of overdose</u></p><p>No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist. <u>Mechanism of action</u></p><p>The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis.Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;- agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late- phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum) and in peripheral blood while improving clinical asthma control.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs - 4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV1: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar</p><p>clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>A clinical study was conducted to evaluate montelukast for the symptomatic treatment of seasonal allergic rhinitis in adult and adolescent asthmatic patients 15 years of age and older with concomitant seasonal allergic rhinitis. In this study, montelukast 10 mg tablets administered once daily demonstrated a statistically significant improvement in the Daily Rhinitis Symptoms score, compared with placebo. The Daily Rhinitis Symptoms score is the average of the Daytime Nasal Symptoms score (mean of nasal congestion, rhinorrhea, sneezing, nasal itching) and the Nighttime Symptoms score (mean of nasal congestion upon awakening, difficulty going to sleep, and nighttime awakenings scores). Global evaluations of allergic rhinitis by patients and physicians were significantly improved, compared with placebo. The evaluation of asthma efficacy was not a primary objective in this study.</p><p>In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period.</p><p>Reduction in EIB was also demonstrated in a short-term study in paediatric patients (maximal fall in</p><p>FEV1 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs - 1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p><u>Distribution</u></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p><u>Biotransformation</u></p><p>Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally, CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based</p><p>on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p><u>Elimination</u></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p><u>Characteristics in Patients</u></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score</p><p>&gt;9).</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of</p><p>saliva, gastrointestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided</p><p>&gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested.</p><p>This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Lactose</li><li>Crosscarmellose sodium</li><li>Colloidal silicone dioxide</li><li>Mg-stearate</li><li>Hypromellose</li><li>Titanium dioxide</li><li>Yellow Iron Oxide</li><li>Red Iron Oxide</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in AluAlu blister pack. Pack size:</p><p>28 Film-coated tablets.</p><p>504 Film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Company (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia 
Tel: 920010564, Fax: +966 (11) 2654723

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>